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ORIGINAL ARTICLE
The impact of proton LET/RBE modeling and robustness analysis on base-of-
skull and pediatric craniopharyngioma proton plans relative to VMAT
A. Gutierreza , V. Rompokosb, K. Lia, C. Gilliesb, D. D’Souzab, F. Soldac, N. Fershtc, Y.-C. Changc, G. Roylea,
R. A. Amosa and T. Underwooda†
aDepartment of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom; bDepartment of
Radiotherapy Physics, University College London Hospitals NHS Foundation Trust, London, United Kingdom; cDepartment of Clinical
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ABSTRACT
Purpose: Pediatric craniopharyngioma, adult base-of-skull sarcoma and chordoma cases are all
regarded as priority candidates for proton therapy. In this study, a dosimetric comparison between
volumetric modulated arc therapy (VMAT) and intensity modulated proton therapy (IMPT) was first
performed. We then investigated the impact of physical and biological uncertainties. We assessed
whether IMPT plans remained dosimetrically superior when such uncertainty estimates were consid-
ered, especially with regards to sparing organs at risk (OARs).
Methodology: We studied 10 cases: four chondrosarcoma, two chordoma and four pediatric cranio-
pharyngioma. VMAT and IMPT plans were created according to modality-specific protocols. For IMPT,
we considered (i) variable RBE modeling using the McNamara model for different values of (a/b)x, and
(ii) robustness analysis with ±3mm set-up and 3.5% range uncertainties.
Results: When comparing the VMAT and IMPT plans, the dosimetric advantages of IMPT were clear:
IMPT led to reduced integral dose and, typically, improved CTV coverage given our OAR constraints.
When physical robustness analysis was performed for IMPT, some uncertainty scenarios worsened the
CTV coverage but not usually beyond that achieved by VMAT. Certain scenarios caused OAR con-
straints to be exceeded, particularly for the brainstem and optical chiasm. However, variable RBE mod-
eling predicted even more substantial hotspots, especially for low values of (a/b)x. Variable RBE
modeling often prompted dose constraints to be exceeded for critical structures.
Conclusion: For base-of-skull and pediatric craniopharyngioma cases, both physical and biological
robustness analyses should be considered for IMPT: these analyses can substantially affect the sparing
of OARs and comparisons against VMAT. All proton RBE modeling is subject to high levels of uncer-
tainty, but the clinical community should remain cognizant possible RBE effects. Careful clinical and
imaging follow-up, plus further research on end-of-range RBE mitigation strategies such as LET opti-
mization, should be prioritized for these cohorts of proton patients.
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Introduction
In this study, we consider adult base-of-skull sarcoma and
chordoma cases plus pediatric craniopharyngioma cases, all
widely regarded as priority candidates for proton therapy.
Base-of-skull tumors (skull base sarcomas, chordomas and
chondrosarcomas) are radio resistant and are particularly
challenging to treat due to their proximity and sometimes
overlap with organs at risk (OARs) such as the brainstem and
optical apparatus. Further, craniopharyngiomas are typically
found in pediatric patients who are sensitive to long-term
radiation effects in normal tissue, for example effects related
to cognitive and endocrinological function [1–3].
It is unsurprising that treatment planning studies demon-
strate that for intracranial tumors proton therapy reduces the
dose of radiation delivered to the whole brain [4]. Further,
across a wide range of base-of-skull tumors, dosimetric stud-
ies have reported that proton plans better spare organs at
risk such as the brainstem, optical apparatus and cochleae
[5–8]. The role of proton therapy in the management of
base-of-skull tumors has also been discussed in a number of
clinical reviews [4,9,10] which consistently suggest that,
relative to photons, protons should be preferred. However,
proton therapy remains a limited resource and both proton
and photon treatments are continuously evolving via advan-
ces such as intensity modulated proton therapy (IMPT) and
volumetric modulated arc therapy (VMAT), respectively.
Additionally, physical and biological uncertainties are much
more complicated for proton plans than for photon plans.
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The ‘robustness’ of proton plans to physical and biological
uncertainties is a topic receiving substantial attention, as
summarized in recent reviews [11,12]. Within commercial
proton treatment planning systems (TPSs), physical uncer-
tainties (both geometrical isocenter shifts and uncertainties
in Hounsfield Unit (HU) to proton stopping power ratio (SPR)
conversion) can not only be analyzed (in terms of dosimetric
effect) but also used to drive plan treatment optimizations
[12]. For skull base tumors, IMPT plans are known to be sen-
sitive (in terms of both target under-dosage and organ at
risk over-dosage) to range and set-up errors [13]. It has been
demonstrated that ‘robust optimization’ can be used to miti-
gate the effects of physical uncertainties for base-of-skull
chordomas and chondrosarcomas [14].
However, thus far no clinical TPS has facilitated easy ana-
lysis of, or treatment optimization based upon, parameters
linked to variable proton biology. A fixed dose-scaling factor
or relative biological effectiveness (RBE) of 1.1 has long been
adopted as a clinical standard to equate the effects of proton
and photon doses across all tissues and biological endpoints
[15]. In vitro it has been demonstrated, however, that proton
RBE is not spatially constant, but dependent on proton linear
energy transfer (LET) values, which rise sharply as protons
reach the end of their range [16–23]. Proton RBE is also
known to depend on the intrinsic biological properties of
the irradiated cells and the exact biological endpoint consid-
ered (e.g., an endpoint of in vitro clonogenic cell survival ver-
sus an endpoint of an in-vivo tissue reaction) [24]. Over
recent years, there have been a number of published warn-
ings on the possible impact of LET upon clinical treatment
plans, including for prostate [25–32], breast [30], thoracic
[27,31], liver [32], head and neck [27,31,33], pituitary [27] and
various brain tumors [31,32,34–36]. These studies consistently
demonstrate that we cannot assume treatment plans to be
robust to uncertainties in proton RBE.
For base-of-skull and pediatric craniopharyngioma treat-
ment plans, we first consider the nominal (error-free) dosi-
metric benefits that IMPT offers over VMAT for up to date
implementations of the two techniques. We then investigate
the impact of IMPT physical and biological uncertainties,
again bringing in comparisons against VMAT. We discuss the
impact of these uncertainties in light of a recent European
Particle Therapy Network (EPTN) consensus document on
radiation dose constraints for organs at risk (OARs) in the
treatment of adult brain tumors [37]. Finally, based on our
findings, we suggest relevant areas for future work.
Material and methods
Patient selection
We studied 10 patients: four chondrosarcoma, two chordoma
and four pediatric craniopharyngioma cases. The dose pre-
scriptions were drawn from our VMAT clinical protocols and
are outlined in Table 1 (for a fair comparison, dose escalation
using protons was not considered). Dose constraints for
OARs were based on standard photon clinical practice at our
center and are also shown in Table 1.
Units
For photon therapy, the standard unit of absorbed dose is
Gy, whereas for proton therapy it is Gy(RBE) [15]. As we ana-
lyzed both photon and proton data, including separate nota-
tions for both Gy and Gy(RBE) would have become
cumbersome at certain points in our manuscript text. At
such points, we have simply written Gy(RBE), where an RBE
of 1 should be assumed for photons. For protons, a standard
RBE of 1.1 should be assumed, unless we specify that we are
using variable RBE modeling (with modeling methods as
described below).
Treatment planning
Both VMAT and IMPT treatment planning were performed
using the Varian (Palo Alto, California, USA) Eclipse TPS, ver-
sion 13.6. CTVs were delineated using magnetic resonance
imaging (MRI), according to tumor-specific national guide-
lines. As our main objective was to assess OAR doses for
VMAT and IMPT (with and without different uncertainty anal-
yses), planning protocols were tailored to the modality.
VMAT treatment planning
For VMAT, the prescriptions shown in Table 1 were assigned
to a PTV which encompassed the CTV plus a uniform margin
of 3mm. Constraints were applied to Planning Risk Volumes
(PRVs) where the raw OARs were expanded by a uniform
margin of 3mm. The VMAT plans we considered were those
delivered clinically at University College London Hospitals
NHS Foundation Trust: for certain cases, the physicians opted
to slightly compromise the OAR dose constraints in order to
improve target coverage. For VMAT, a dual 6MV arc
(RapidArc) technique was considered.
IMPT treatment planning
Multi-field robust optimization was implemented in Eclipse
using Nonlinear Universal Proton Optimizer version 13.7.16,
which performs a voxel-wise ‘worst-case’ optimization. The
‘worst-case’ (also known as ‘minimax’) approach determines
the IMPT plan which is as good as possible for the worst
error scenario [12,38,39]. Within the robust optimization,
Table 1. Our dose prescriptions and organ at risk dose constraints for VMAT
and proton plans, drawn from clinical VMAT protocols at our center.
Chondrosarcomas
and chordoma
Paedriatic
craniopharyngioma
Total dose prescription [Gy(RBE)] 65.13 50.4
Number of fractions 39 28
Organ at risk Volume [cm3] Constraint [Gy(RBE)] Constraint [Gy(RBE)]
Brainstem 0.1 58 50.4
Spinal cord 0.1 58 50
Optic nerves 0.1 58 50
Optic chiasm 0.1 58 50
Retina Max <49 Max <45
Lenses Max <6.5 Max <6
Inner ear Mean 52 Mean 44
Parotid Mean 30
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geometrical uncertainties of ±3mm and range uncertainties
of ±3.5% were considered. The magnitude of proton range
uncertainty due to HU to SPR conversion was assumed pro-
portional to the distance traversed through tissue (the max-
imum range of the beam), as routinely considered in clinical
proton margin recipes [40].
Proton plans used a 4-field star arrangement, with fixed
gantry and couch rotations as specified in Supplementary
Table 1. A relatively high number of proton fields (4) was
used to reduce the impact of uncertainties associated with
any single field and the field arrangement was selected to (i)
limit beam passage through heterogeneous regions of the
skull and (ii) position the distal fall-off of the beams away
from critical organs at risk as far as possible [41]. The beam
angles were chosen so that the inferior–anterior–lateral
beams were approximately tangential to the optic structures
and the superior–lateral beams were not ranging out within
the brainstem as shown in Supplementary Figure 1. For
these plans, the dose constraints were rigidly applied to the
raw OARs, the robust optimization process being used to
limit the impact of geometric and range uncertainties. In the
remainder of the manuscript, dose reported in the error-free
scenario is referred to as the nominal case. Also, note that
the plans were optimized using a constant RBE of 1.1, with
variable RBE values being calculated post-optimization for
the nominal IMPT plans.
Regarding IMPT robustness analysis, 12 scenarios were
considered: ±3.5% CT number to SPR conversion uncertain-
ties, combined with ±3mm shifts of the isocenter in x, y and
z directions, as shown in Supplementary Table 2. Where
‘worst case’ IMPT results are reported, these consider the
scenario within Supplementary Table 2 that returns the high-
est value for the OAR dose metric under consideration/the
lowest value for the CTV dose metric under consideration.
The ‘worst case’ robustness analysis assumes that the same
error is realized systematically throughout the course of
the treatment.
Variable RBE using the McNamara model and LETd
calculation
Various RBE models have been developed over recent years,
with broadly consistent trends [27,34]. For the calculation of
a variable RBE in our proton plans, we used the McNamara
model [42], a phenomenological model based on the linear
quadratic model and a highly comprehensive input database.
In this model, a compilation of all RBE experimental meas-
urements available before 2014 (287 experimental data
points) was used for a nonlinear regression fit of the RBE as
a function of the proton dose (Dp), dose-averaged LET (LETd)
and the ratio (a/b)x. The McNamara model predicts increased
RBE values for low (a/b)x as well as for high LETd. It predicts
neither particularly high nor low RBE values relative to other
model options [27].
The McNamara RBE model was applied in Matlab using
in-house code which extended the CERR open source soft-
ware [43]. We primarily utilized (a/b)x ¼ 2Gy, a value typic-
ally considered for late-reacting brain tissue [37], but we also
included data using (a/b)x values of 3 Gy and 4Gy for com-
parison. For simplicity, we generally considered matched
(a/b)x values for both normal and tumor tissues. Reliable clin-
ical data on tumor (a/b)x values for chondrosarcoma, chor-
doma and pediatric craniopharyngioma tumors are scarce: a
recent literature search [44] found only one relevant study
which estimated an (a/b)x of 2.45Gy for chordoma [45].
A much higher tumor (a/b)x of 10Gy was also applied in our
consideration of CTV coverage. The LETd used in the
McNamara model was calculated using an analytical model
based upon work from Sanchez-Parcerisa et al. [46], imple-
mented for each plan directly within Eclipse (using code
released to us by Varian Medical Systems of Palo Alto,
California, USA). The dose threshold for the LETd calculation
script was 0.5% of the plan’s maximum dose value. At the
time of writing, the Varian analytical LETd script did not sup-
port range shifters: we considered centrally located tumors
where range shifters were not required.
Analysis considering dose constraints from the
EPTN consensus
In the recent EPTN manuscript on radiation dose constraints
for OARs in the treatment of adult brain tumors, constraints
were reported as equivalent dose in 2Gy(RBE) fractions and
(a/b)x ¼ 2Gy was assumed for the brain, brainstem and optic
chiasm [37]. To consider our results in light of these pub-
lished dose constraints [37], we transferred relevant brain,
brainstem and optic chiasm constraints to our adult fraction-
ation scheme (as reported in Table 1) using the concept of
equivalent biological effective dose (BED) [47].
We used the equivalent BED formula:
D1 ¼
D2 1þ d2a
b
 
1þ d1a
b
  (1)
to calculate D1: the total BED isoeffective dose constraint
for our fractionation scheme, from d1: our 1.67 Gy(RBE) dose
per fraction for adult chondrosarcoma and chordoma
patients (Table 1).
D2: each total dose constraint published by the EPTN [37].
d2: the 2Gy(RBE) dose per fraction considered by the
EPTN [37].
(a/b)x: the 2Gy(RBE) value for (a/b)x considered by the
EPTN [37].
The resulting constraints are included in Supplementary
Table 3. In the EPTN report, a higher dose constraint is pro-
posed for the brainstem ‘surface’, compared to the brainstem
‘interior’. As we considered the EPTN constraints only in our
plan analysis, not optimization, for simplicity we considered
whether the stricter ‘interior’ constraint was met for our com-
plete brainstem structures.
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Results
Adult cases: Nominal results assuming a fixed RBE
of 1.1
Figure 1 shows the dose volume histograms (DVHs) of the
CTV coverage and doses delivered to OARs for all of the
adult (chondrosarcoma and chordoma) cases: six patients in
total. In this section, we focus on comparing VMAT and nom-
inal, robustly optimized, IMPT with RBE ¼ 1.1.
The mean doses to 95% of the CTV were (88 ± 1)% and
(91 ± 4)% of the prescription dose for VMAT and IMPT,
respectively (Figure 1(a)). Generally, the IMPT approach
delivered improved CTV coverage given the prioritized OAR
constraints.
To compare dose levels within the normal brain for the
two modalities, we plotted the DVHs of the brain structure
minus CTV (Figure 1(b)). As expected, IMPT outperformed
VMAT in this regard with a lower mean dose of (5.2 ± 1.3)
Gy(RBE), compared to (12.2 ± 2.9) Gy (VMAT).
DVHs for the brainstem are shown in Figure 1(c).
We can see that the nominal IMPT scenario achieved a
lower mean dose for this OAR: the mean dose for IMPT
is (24.5 ± 4.6) Gy(RBE) compared to (42.2 ± 4.0) Gy for
VMAT.
Figure 1. Chordoma and chondrosarcoma cases. DVHs of nominal IMPT (solid black lines) with RBE ¼ 1.1 and VMAT (dash red lines). The gray shaded area repre-
sents the robustness analysis IMPT scenarios and the dotted green lines are the McNamara model using (a/b)x ¼ 2 Gy. The blue solid line represents the dose con-
straint at 58 Gy(RBE).
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However, for the optical chiasm, both approaches resulted
in similar nominal dosimetry due to the structure’s small size
and the fact that the majority of its volume was located
within the target: this OAR was typically irradiated up to our
dose constraint without slack for dose sparing (Figure 1(d)).
The mean dose to the optical chiasm was (54.9 ± 3.5) Gy(RBE)
and (56.0 ± 0.7) Gy for IMPT and VMAT, respectively.
As shown in Figure 1(e,f), the dose to the optic nerves
was generally well-controlled relative to our 58Gy(RBE) dose
constraint. However, IMPT better spared the optic nerves: the
mean optic nerve dose for IMPT was (24.8 ± 12.8) Gy(RBE),
compared to (36.3 ± 7.7) Gy for the VMAT. The higher VMAT
mean dose is attributable to the geometrical implementation
of arc therapy, where patients’ lenses and optic nerves
necessarily fell within the radiation path.
A summary of mean and maximum doses for the CTV and
OARs are shown in Supplementary Table 4.
Adult cases: Results considering the IMPT physical
robustness analysis and a fixed RBE of 1.1
The physical robustness analysis scenarios are plotted in
Figure 1, as a shaded area constrained by the worst and best
cases, alongside results for VMAT and nominal IMPT.
Figure 1(a) considers the CTV, where the worst case phys-
ical uncertainty scenarios diminished coverage but typically
not beyond that achieved by VMAT. In fact, when the worst
case was considered, coverage fell from 91± 4 to 89 ± 3% of
the prescribed dose for 95% of the CTV volume, relative to
88± 1% for VMAT.
Concerning the brain-CTV volume (Figure 1(b)), the robust
analysis scenarios did not diminish the advantages of IMPT
over VMAT.
For OAR sparing, some physical uncertainty scenarios
caused our dose constraints to be exceeded for IMPT. For
example, when considering the worst-case scenario, our
brainstem dose constraint was exceeded for all adult patients
(Figure 1(c)). Overall, 60% of the physical robustness scen-
arios (43 out of 72 different scenarios for the six adult
patients) exceeded our brainstem dose constraint. The mean
volume of the brainstem irradiated by our dose constraint
(for the worst case scenario) was (1.6 ± 0.3) cm3, about 10
times higher than the 0.1 cm3 maximum volume considered
in our clinical protocol. For four out of six patients, our dose
constraint for the optic chiasm was exceeded when the
worst case scenario was considered (Figure 1(d)). On the con-
trary, our optic nerve dose constraint to 0.1 cm3 was
exceeded for just one patient for the worst case of IMPT
physical uncertainty (see Figure 1(e,f)).
Adult cases: Results considering variable RBE modeling
using the McNamara model and (a/b)x 5 2Gy
To assess the impact of applying LETd and variable RBE mod-
eling, Figure 1 also shows the DVHs plots for VMAT, nominal
IMPT (RBE ¼ 1.1) and IMPT using the McNamara model with
(a/b)x ¼ 2Gy. The variable RBE model predicted a substantial
increase of dose for both the CTV and the OARs. Such an
increase was expected since variable RBE models predict the
greatest elevation in RBE (above 1.1) for tissues with low
(a/b)x ratios [34]. Applying the RBE modeling with (a/b)x ¼
2Gy, the mean dose to 95% of the CTV volume became
100 ± 3% of the prescribed dose, corresponding to an
increase of (5.7 ± 3.0) Gy(RBE) relative to nominal IMPT with
RBE ¼ 1.1. However, considering a higher (a/b)x value of
10Gy for the target, the mean dose to 95% of the CTV vol-
ume was reduced to only 89 ± 3% of the prescribed dose
(less than the nominal IMPT case).
When the variable RBE modeling was applied to the
brainstem, our dose constraint was exceeded for all six adult
patients, the mean volume irradiated at our dose constraint
becoming 4.1 ± 1.8 cm3. The variable RBE modeling also
resulted in 100% of the optic chiasm volume being irradiated
at or above our dose constraint for four of the six adult cases
(Figure 1(d)). Similarly, our dose constraint was surpassed for
five out of 12 optic nerve volumes (Figure 1(e,f)).
Pediatric cases: Summary of the results for all
modalities and analyses
Results for our four pediatric craniopharyngioma cases are
included in Figure 2.
Comparing VMAT against nominal IMPT with constant RBE
¼ 1.1, the target coverage was similar for both, with 95% of
the CTV volume receiving 98 ± 1% and 98± 0.1% of the pre-
scribed dose for VMAT and nominal IMPT, respectively. CTV
coverage remained acceptable for all of the IMPT physical
robustness scenarios. Application of the variable RBE model
again boosted the dose to the CTV.
As for the adult cases, IMPT spared the normal brain bet-
ter than VMAT (see Figure 2(b)), regardless of whether
robustness analysis or variable RBE modeling was considered.
For OARs, however, the variable RBE modeling caused our
brainstem and optic chiasm constraints to be exceeded for
all patients and our optic nerve constraints to be exceeded
for 2/4 patients.
Detailed results for an example chordoma case
In this section, we focus on one chordoma case which we
selected as the CTV coverage achieved was very similar for
the VMAT and nominal IMPT treatment plans. However, com-
parable trends were observed for all other patients.
Supplementary Figure 2 shows the resulting dose-maps
for the two approaches, plus the LETd and variable RBE-
weighted dose calculations for the IMPT treatment plan. As
noted target coverage was similar for both the IMPT and
VMAT plans, and as expected the integral doses outside the
CTV (within the OARs and normal tissues) were higher for
VMAT (see Supplementary Figure 2(a,b)). Application of the
McNamara model led to a dose increase of up to 8Gy(RBE)
outside the CTV volume, particularly at the edge of the
brainstem. Two high intensity spots are visible at each side
of the CTV in supplementary Figure 2(d), indicating that the
beam arrangement (in this case the four-field star arrange-
ment with beams from the left and right, as shown in
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Supplementary Figure 1), has a major impact on modeled
LETd and RBE maps.
Figure 3 shows the dose-difference maps for several
approaches. For example, Figure 3(a) illustrates VMAT versus
nominal IMPT (RBE ¼ 1.1), with differences up to 30Gy(RBE).
These high differences are attributable to the contrasting
treatment geometries (360 beam angles for VMAT as
opposed to four fixed fields for IMPT) and occur mainly in
the nasal cavities and around the optical nerves. There is
also a substantial dose-difference across the brainstem,
reflective of the fact that IMPT reduces the mid/low dose
bath to OARs for similar target coverage. Figure 3(b) shows
the dose-difference maps for VMAT versus nominal IMPT
with variable RBE with (a/b)x ¼ 2Gy. If we compare both
IMPT plans (variable RBE vs constant RBE), as shown in
Figure 3(c), there is a clear excess in biological dose, particu-
larly at the lateral sides of the CTV.
Supplementary Figure 3 shows the patient’s DVHs for
VMAT, nominal robustly optimized IMPT (RBE ¼ 1.1), physical
robustness analysis IMPT (RBE ¼ 1.1) and IMPT with variable
RBE ((a/b)x ¼ 2Gy). CTV dose coverage was generally pre-
served regardless of the IMPT physical robustness scenario
Figure 2. Four pediatric cases. DVHs of nominal IMPT (solid black lines) with RBE ¼ 1.1 and VMAT (dash red lines). The gray-shaded area represents the robustness
analysis IMPT scenarios and the dotted green lines are the McNamara model using (a/b)x ¼ 2 Gy. The blue solid line represents the dose constraint at 50.4 Gy(RBE)
for the brainstem and 50 Gy(RBE) for other OARs.
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considered (Supplementary Figure 3(a)). Regarding OARs, our
brainstem dose constraint was substantially exceeded for
both (worst case) IMPT robust analysis and IMPT with vari-
able RBE (respectively, 1.9 and 2.2 cm3 of brainstem received
doses in excess of our constraint). 0.2 and 0.6 cm3 of the
optic chiasm received doses in excess of our constraint for
worst case IMPT robustness analysis and IMPT analysis with
variable RBE, respectively. The total optic chiasm volume for
this patient was in fact 0.6 cm3, such that the complete struc-
ture received doses in excess of our constraint when variable
RBE modeling was considered.
Summarizing the impact of physical and biological
uncertainties on the OARs
Figure 4(a) considers the volume of brainstem irradiated at
or above our dose constraints (58Gy(RBE) for the adult pre-
scriptions and 50.4 Gy(RBE) for the pediatric prescriptions) for
the different treatment modalities and analyses. Within the
nominal VMAT and robustly optimized IMPT treatment plans,
generally less than 0.1 cm3 of the brainstem received doses
at or exceeding these constraints. However, when the IMPT
robustness analysis was performed and the worst-case scen-
arios were considered (assuming an RBE of 1.1), a spread in
the volume arose, with an average of 1.0 ± 0.8 cm3 of the
brainstem being irradiated to doses at or above our con-
straint. Further, when biological uncertainties were consid-
ered using the McNamara variable RBE model, there was an
increase in and an amplified spread in the brainstem volume
which received doses exceeding the constraint. The spread
was more pronounced for low (a/b)x, where a greater
increase in biological dose was expected. Average volumes
of 4.0 ± 2.7 cm3, 3.0 ± 2.4 cm3 and 2.2 ± 2.2 cm3 received doses
in excess of our constraint when (a/b)x was modeled as 2Gy,
3Gy and 4Gy, respectively.
Figure 4(b) shows the volume of optic chiasm irradiated
at or above our dose constraint. We observed a trend similar
to that for the brainstem except that, for many patients,
decreasing the (a/b)x did not impact upon y-axis results. This
is because 100% of the optic chiasm was already irradiated
at our dose constraint when variable RBE was considered,
even for high (a/b)x (e.g., 4 Gy). More outliers were observed
for this OAR, likely due to its relatively small abso-
lute volume.
For the adult cases, Supplementary Table 5 considers
whether the EPTN brain, brainstem and optic chiasm dose
constraints [37] (transferred to our fractionation scheme
(Supplementary Table 3)) were exceeded for each patient
and each scenario. Supplementary Table 5 reinforces the
point is that it is the variable RBE modeling, rather than the
worst-case IMPT has the strongest impact upon constraint
breach/fulfilment.
Discussion
In this work, we modeled the impact of physical and bio-
logical uncertainties on base-of-skull IMPT treatment plans
which were produced in the Varian Eclipse TPS using physic-
ally ‘robust optimization’. Optimization based upon biologic-
ally relevant parameters such as LETd is not yet available in
clinical treatment planning systems. Consistent with pub-
lished studies [25–31] our findings demonstrated that base-
of-skull IMPT plans deemed acceptable under the assump-
tion of a fixed RBE (1.1) did not satisfy OAR constraints when
variable RBE modeling was applied. We additionally found
the impact of variable RBE modeling to be greater than that
of the physical ‘worst case’ analysis. Comparisons between
the adult and pediatric groups depended on the OAR, likely
due to complex interplays between the dose prescriptions,
constraints and target/OAR geometries. For example, for the
brainstem, the physical robustness problem was more critical
for adults than pediatric patients. For the optic chiasm, prob-
lems with physical robustness were consistently evident for
both groups. Consistently, variable RBE modeling strongly
impacted upon volume of these OARs irradiated at or above
our dose constraints.
We calculated voxelized LETd maps using an analytical
model based upon the work of Sanchez-Parcerisa et al [46],
using a script released to us by Varian Medical Systems (Palo
Alto, CA, USA). For a single pediatric brain tumor, good
agreement has previously been presented between variable
RBE (McNamara model) weighted DVHs calculated using LETd
(i) from the Sanchez-Parcerisa analytical model and (ii) from
full Monte Carlo simulations [46]. Further work however
could usefully investigate the accuracy of the analytical LETd
script provided by Varian under a range of clinical circum-
stances. The suitability, or otherwise, of averaged LET as a
Figure 3. (a) Dose-difference maps for VMAT minus nominal IMPT (RBE ¼ 1.1) (b) VMAT minus nominal IMPT (variable RBE with (a/b)x ¼ 2 Gy) and (c) IMPT (vari-
able RBE with (a/b)x ¼ 2 Gy) minus IMPT (RBE ¼ 1.1). CTV is outlined in black, the brainstem in red and the optic nerves are in blue.
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surrogate for biological effect also warrants further investiga-
tion [48].
Uncertainties in (i) the McNamara RBE model [42] (and its
transferability from in vitro experiments to real patients) and
(ii) (a/b)x values, necessarily limit our interpretation of the
absolute variable RBEw dose values we present. The trends
however, are clear and ‘best guess’ modeling indicates that
OAR constraints (e.g., from the EPTN [37]) primarily based on
photon radiotherapy will sometimes be exceeded when pro-
ton RBE effects are considered. Our results emphasize the
pressing need for further research to consider how IMPT
plans can be optimized to be robust to both physical and
biological uncertainties. The design of base-of-skull IMPT
plans which are biologically robust, physically robust and
clearly superior to VMAT in terms of OAR sparing, is non-triv-
ial. Worldwide, considerable effort is being applied to the
development of new methods for (i) robust IMPT optimiza-
tion based on physical and biological parameters and (ii)
IMPT robustness analyses [48]. ‘Worst case’ uncertainty scen-
arios (as employed in the commercial TPS we used)
are sometimes criticized for being overly conservative
[48]: stochastic or probabilistic approaches form an active
area of research and a viable alternative [12]. To date, rela-
tively little research has been performed on robust optimiza-
tion and robustness reporting in photon therapy [49,50]:
additional work in this area could facilitate fairer dosimetric
comparisons between treatment modalities. Ultimately, inter-
and intra-fraction variations in anatomy could also be consid-
ered as part of the robustness problem [51]. Thus far, non-
clinical proof of principle demonstrations have shown that
LET optimization can, in some cases, be implemented at little
cost to IMPT physical dose [52–54]. The rationale to further
explore and clinically implement LET-based optimization (to
push hotspots away from critical OARs at little cost to target
dose distributions) is clearly strong for base-of-skull tumors
and pediatric craniopharyngioma. Furthermore, IMPT beam
configuration is of paramount importance and additional
proton beam angles (moves towards proton arc therapy),
may be required if IMPT is to outperform VMAT in a truly
robust manner.
The limited clinical evidence for variable proton RBE
effects within the brain was recently summarized by L€uhr
Figure 4. Volume of (a) brainstem and (b) optical chiasm irradiated at or above our dose constraints (58 Gy(RBE) for the adult prescriptions and 50.4 Gy(RBE) for
the pediatric prescriptions) for the different treatment modalities and analyses. The mean is drawn as a dashed line, the median as a solid line and the whiskers
are drawn to maximum 1.5  iqr (interquartile range).
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et al. [55] who emphasized the need for further ‘clinical’ RBE
data to be obtained from in vivo RBE studies and patient
outcome analyses. It is evident that careful clinical follow-up
should be prioritized in prospective patient studies.
Additionally, quantitative imaging might prove useful in
investigating possible correlations between normal tissue
damage and LET/RBE [56].
Conclusions
When comparing VMAT and nominal IMPT plans for our
base-of-skull cohort, the dosimetric advantages of IMPT are
clear: IMPT leads to reduced integral dose (especially to the
normal brain) and generally to improved CTV coverage given
the OAR constraints. Within our physical robustness analysis,
some robustness scenarios returned IMPT plans which
exceeded dose constraints (both our local VMAT dose con-
straints and those recently proposed by the EPTN) for small
volumes of critical organs of risk, especially the brainstem.
However, variable RBE-weighted dose analyses predicted
even more substantial dose-boosts/hotspots within the brain-
stem and optical chiasm.
In conclusion, both physical and biological robustness
analyses should be considered for IMPT treatment plans for
base-of-skull and pediatric craniopharyngioma cases. These
analyses can substantially affect the sparing of OARs (e.g.,
relative to the EPTN constraints) and comparisons relative to
VMAT. It is desirable to assess different beam arrangements
to minimize possible dose excesses due to both physical and
biological uncertainties. All proton RBE modeling is subject
to high levels of uncertainty, but the clinical community
should remain cognizant of possible variable RBE effects.
Further, clinical implementation of end-of-range RBE mitiga-
tion strategies (such as LET-based optimization) should be
prioritized for base-of-skull tumors, alongside careful clinical
and imaging follow-up.
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